Previous Article | Next Article 
Journal of Virology, June 2000, p. 5709-5711, Vol. 74, No. 12
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Application of the Intracellular Gamma Interferon
Assay To Recalculate the Potency of CD8+ T-Cell
Responses to Herpes Simplex Virus
Udayasankar
Kumaraguru and
Barry T.
Rouse*
Department of Microbiology, University of
Tennessee, Knoxville, Tennessee 37996-0845
Received 2 February 2000/Accepted 24 March 2000
 |
ABSTRACT |
Enumeration and characterization of herpes simplex virus
(HSV)-specific CD8+ T lymphocytes are tedious and indirect.
We quantitated antigen-specific CD8+ T cells during acute
and secondary stages of HSV infection using intracellular gamma
interferon production upon stimulation with virus or immunodominant
peptide. Results show a substantial increase in the number of
CD8+ T cells which was otherwise underestimated with the
conventional limiting dilution analysis.
 |
TEXT |
Quantifying virus-specific cytotoxic
T lymphocyte (CTL) responses by the tedious limiting dilution analysis
(LDA) technique indicated that the immune response to viruses involves
surprisingly few cells. This was especially notable with herpes simplex
virus (HSV), with which, even at its peak, the number of CTL precursors detectable by LDA was in the 1/1,000 to 1/2,000 range (6). The advent of major histocompatibility complex tetramers as well as the
detection by fluorescence-activated cell sorting (FACS) or ELISPOT of
peptide-stimulated CD8+ T cells that produce intracellular
gamma interferon (IFN-
) has rewritten the numbers book
(3-5). Remarkably, in fact, with lymphocytic choriomeningitis virus during the acute phase, lymphocytic
choriomeningitis virus-specific CD8+ T cells reach 70% of
the total CD8+ population and represent as many as 50%
long into the memory phase. In this report, we have applied the
antigen-driven intracellular IFN-
(ICG) assay to measure the
CD8+ T-cell response of C57BL/6 and BALB/c mice to HSV
infection and have compared it to LDA. Our results show far greater
numbers of cells detected by the ICG assay (around 100-fold), but the maximum percentage of cells detectable in virus-stimulated splenic CD8
T cells was less than 4% and by 90 days was less than 1%.
C57BL/6 and BALB/c mice were infected with 5 × 106
PFU of HSV(kos) in the footpad. The spleens were removed from these
animals at different time points after infection for LDA and ICG
analyses to assess the frequency of HSV-specific CD8+ T
cells as CTL precursors (CTL-p) and effector CTLs (eCTL), respectively. C57BL/6 and BALB/c splenocytes were stimulated with HSV(kos)-infected (at a multiplicity of infection of 5) and X-ray-irradiated syngeneic cells (MC38 and EMT6, respectively) for 10 to 12 h. A portion of
C57BL/6 splenocytes was also stimulated with SSIEFARL
(HSVgB498-505[synthesized at Genemed Synthesis,
Inc., San Francisco, Calif.]) peptide (1 mg/ml) for 6 h, in a
96-well flat-bottomed plate at a concentration of 106
cells/well in a volume of 0.2 ml of complete medium (RPMI 1640-10% fetal bovine serum) supplemented with 50 U of human recombinant interleukin 2. Brefeldin A was added at the beginning of the
peptide-stimulated splenocyte cultures, while virus-stimulated cultures
received brefeldin A during the last 5 h of the culture period.
The period of stimulation and the doses of peptide and virus used were
optimal based on the results of initial experiments. The cells were
harvested after the incubation period, washed with RPMI 1640, and
resuspended in FACS buffer (phosphate-buffered saline containing 3%
fetal bovine serum and 1 mM NaN3). The cells were surface
stained for CD8 (fluorescein isothiocyanate [FITC]-labeled anti-CD8a)
or CD69 (FITC-labeled anti-CD69 early activation marker) or CD44
(FITC-labeled anti-CD44) or CD62L (FITC-labeled anti-CD62L) for 30 min.
The unbound antibodies were washed, and the cells were analyzed for intracellular IFN-
per the protocol described for intracellular staining in the kit purchased from Pharmingen (Becton Dickinson). The
phycoerythrin-labeled anti-IFN-
and its isotype antibody control and
other antibodies used in the staining were all purchased from
Pharmingen. The stained cells were immediately analyzed using the
FACScan (Becton Dickinson) and CellQuest software. As a positive control for the intracellular staining procedure, polyclonal
stimulators phorbol myristate acetate (50 ng/ml) and ionomycin (500 ng/ml) were used (data not shown).
The LDA was performed as previously described (6). Frequency
estimates of CTL-p were made using the minimal
2 method
described by Taswell (7).
With HSV, few peptides have been identified which act as
CD8+-recognized epitopes. The notable exception is
SSIEFARL (amino acids 498 to 505), which acts as an
immunodominant epitope in C57BL/6 mice (2). Previous reports
with other viruses (3-5, 9) using the ICG assay have all
used peptide stimulation to drive intracellular IFN-
expression.
Lacking such peptides to stimulate BALB/c HSV-immune CD8 cells to
produce intracellular IFN-
, virus stimulation was used. As is
evident in Table 1, when the same
population of splenocytes from HSV-immune BALB/c mice was analyzed for
CTL-p by LDA and for eCTL by the ICG assay, the latter assay detected
around 100-fold greater frequencies. In the day 14 sample, for example,
the CD8+ eCTL accounted for 2.8% (range, 2.6 to 3.3% in
three experiments) of the total CD8 population and had fallen to <2%
by day 60. However, by day 60, CTL-p frequencies had decreased even
more and were on the borderline of being too low to accurately compute.
For C57BL/6 mice (Table 2), the ICG assay
was used to measure both peptide- and virus-stimulated responses. When
the two were compared in parallel, greater eCTL frequencies were always detected by peptide stimulation, although differences were usually greater than twofold. An explanation for this finding is not at hand.
However, it could relate both to the fact that SSIEFARL is an
overwhelmingly dominant epitope in C57BL/6 mice (8) and the
fact that when peptides are used for CTL recognition, a wider affinity
spectrum of CTLs is recorded. Comparisons between LDA and the ICG assay
with the same cell population in the C57BL/6 system always used peptide
to stimulate intracellular IFN-
expression. In such comparisons, the
eCTL approach detected around 80-fold higher frequencies than CTL-p at
14 days and 470-fold at 60 days (Table 2). Several other time periods
after HSV infections were tested for peptide-stimulated ICG responses
in C57BL/6 mice. At peak times (14 days), responses were between 5 and
6% of the total CD8+ splenocytes and by 90 days had
declined to <1%. However, cells detected at 90 days were still
considered above background and specific. Finally, additional
phenotypes were measured on the IFN-
-positive cells. After day 14, samples of all IFN-
+ cells were judged to be of the
memory/effector phenotype in additional to being CD44hi and
CD62Llo and also expressing CD69 (Fig.
1).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
Phenotype of the IFN- + cells. Splenocytes
were surface stained for CD44, CD62L, or CD69 FITC-labeled antibody and
followed by intracellular staining with phycoerythrin-labeled
anti-IFN- . The same region which was gated to analyze
CD8+ IFN- + cells was applied to these
analyses.
|
|
In conclusion, this note reports for the first time the value of the
intracellular IFN-
assay to quantify HSV-specific CD8+
T-cell responses in mice. We anxiously await major histocompatibility complex tetramers and expect these will soon be available soon for at
least the peptide SSIEFARL in C57BL/6 mice (S. S. Tevethia, personal communication). To take full advantage of new technology to
better understand the role of CD8+ T cells in immunity of
humans and experimental animals requires that more CD8-recognized
epitopes be defined. We and others are participating in this objective.
 |
ACKNOWLEDGMENTS |
This work was supported by grants AI 14981 and AI 46462.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: M409 Walters
Life Sciences Bldg., University of Tennessee, Knoxville, TN 37996-0845. Phone: (865) 974-4026. Fax: (865) 974-4007. E-mail:
btr{at}utk.edu.
 |
REFERENCES |
| 1.
|
Alexander-Miller, M. A.,
G. R. Leggatt, and J. A. Berzofsky.
1996.
Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
Proc. Natl. Acad. Sci. USA
93:4102-4107[Abstract/Free Full Text].
|
| 2.
|
Blaney, J. E., Jr.,
E. Nobusawa,
M. A. Brehm,
R. H. Bonneau,
L. M. Mylin,
T. M. Fu,
Y. Kawaoka, and S. S. Tevethia.
1998.
Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.
J. Virol.
72:9567-9574[Abstract/Free Full Text].
|
| 3.
|
Butz, E. A., and M. J. Bevan.
1998.
Massive expansion of antigen-specific CD8+ T cells during an acute virus infection.
Immunity
8:167-175[CrossRef][Medline].
|
| 4.
|
Callan, M. F. C.,
N. Steven,
P. Krausa,
P. A. H. Moss,
J. D. K. Wilson,
J. I. Bell,
A. B. Rickson, and A. J. McMichael.
1996.
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis.
Nat. Med.
2:906-911[CrossRef][Medline].
|
| 5.
|
Murali-Krishna, K.,
J. D. Altman,
M. Suresh,
D. Sourdive,
A. Zajac,
J. Miller,
J. Slansky, and R. Ahmed.
1998.
Counting antigen specific CD8+ T cells: a re-evaluation of bystander activation during viral infection.
Immunity
8:177-187[CrossRef][Medline].
|
| 6.
|
Rouse, B. T.,
H. S. Larsen, and H. Wagner.
1983.
Frequency of cytotoxic T lymphocyte precursors to herpes simplex virus type 1 as determined by limiting dilution analysis.
Infect. Immun.
39:785-792[Abstract/Free Full Text].
|
| 7.
|
Taswell, C.
1981.
Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.
J. Immunol.
126:1614-1620[Abstract].
|
| 8.
|
Wallace, M. E.,
R. Keating,
W. R. Heath, and F. R. Carbone.
1999.
The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant.
J. Virol.
73:7619-7626[Abstract/Free Full Text].
|
| 9.
|
Wilson, J. D. K.,
G. S. Ogg,
R. L. Allen,
P. J. R. Goulder,
A. Kelleher,
A. K. Sewell,
C. A. O'Callaghan,
S. L. Rowland-Jones,
M. F. Callan, and A. J. McMichael.
1998.
Oligoclonal expansion of CD8+ T cells in chronic HIV infection are antigen specific.
J. Exp. Med.
188:785-790[Abstract/Free Full Text].
|
Journal of Virology, June 2000, p. 5709-5711, Vol. 74, No. 12
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sarangi, P. P., Sehrawat, S., Suvas, S., Rouse, B. T.
(2008). IL-10 and Natural Regulatory T Cells: Two Independent Anti-Inflammatory Mechanisms in Herpes Simplex Virus-Induced Ocular Immunopathology. J. Immunol.
180: 6297-6306
[Abstract]
[Full Text]
-
Bharhani, M. S., Grewal, J. S., Peppler, R., Enockson, C., London, L., London, S. D.
(2007). Comprehensive phenotypic analysis of the gut intra-epithelial lymphocyte compartment: perturbations induced by acute reovirus 1/L infection of the gastrointestinal tract. Int Immunol
19: 567-579
[Abstract]
[Full Text]
-
Toka, F. N., Rouse, B. T.
(2005). Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. J. Leukoc. Biol.
78: 178-186
[Abstract]
[Full Text]
-
Toka, F. N., Suvas, S., Rouse, B. T.
(2004). CD4+ CD25+ T Cells Regulate Vaccine-Generated Primary and Memory CD8+ T-Cell Responses against Herpes Simplex Virus Type 1. J. Virol.
78: 13082-13089
[Abstract]
[Full Text]
-
Yang, T. C., Dayball, K., Wan, Y. H., Bramson, J.
(2003). Detailed Analysis of the CD8+ T-Cell Response following Adenovirus Vaccination. J. Virol.
77: 13407-13411
[Abstract]
[Full Text]
-
Toka, F. N., Gierynska, M., Rouse, B. T.
(2003). Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1. J. Virol.
77: 12742-12752
[Abstract]
[Full Text]
-
Suvas, S., Kumaraguru, U., Pack, C. D., Lee, S., Rouse, B. T.
(2003). CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses. JEM
198: 889-901
[Abstract]
[Full Text]
-
Kumaraguru, U., Gierynska, M., Norman, S., Bruce, B. D., Rouse, B. T.
(2002). Immunization with Chaperone-Peptide Complex Induces Low-Avidity Cytotoxic T Lymphocytes Providing Transient Protection against Herpes Simplex Virus Infection. J. Virol.
76: 136-141
[Abstract]
[Full Text]
-
Eo, S. K., Kumaraguru, U., Rouse, B. T.
(2001). Plasmid DNA Encoding CCR7 Ligands Compensate for Dysfunctional CD8+ T Cell Responses by Effects on Dendritic Cells. J. Immunol.
167: 3592-3599
[Abstract]
[Full Text]
-
Kumaraguru, U., Davis, I. A., Deshpande, S., Tevethia, S. S., Rouse, B. T.
(2001). Lymphotoxin {{alpha}}-/- Mice Develop Functionally Impaired CD8+ T Cell Responses and Fail to Contain Virus Infection of the Central Nervous System. J. Immunol.
166: 1066-1074
[Abstract]
[Full Text]